RE:RE:RE:RE:RE:Investing chat rooms like this....You just made my point. Care Oncology revenue has now replaced Covid. That part of the business is bringing in revenue and almost cashflow positive. A good pivot to keep the company moving forward.
With Aristotle growth it will move the company forward.
But hey keep bashing a company doing what it needs to, to move forward, employee nearly 50 people and save lives.
Every quarter is getting better despite your tired rants and obvious agenda.
Liked2Think wrote: They havent gained traction with workplaces, employer groups, mercer etc for over a year and thats after years of supposedly dealing with them for covid
"come for covid stay for cancer"
did anyone stay for cancer? doesnt look like it
Same as with a tech company. Why would it take so long to sign up one of those groups if the product was actually good? They had years to push their previous cancer tests, and 2 years to push their company via covid testing and what has it got the investors?
Without the CARE purchase where would they be now?
There is no doubt this is taking much longer than anyone expected but hard to argue the numbers with revenue from Care Oncology and reduced costs showing improvement. When they gain traction with workplaces, employer groups, Mercer etc it will move the overall business to cash flow positive.